Although the mechanisms underlying the association between serum KL-6 and mortality risk in patients with CTD-ILD deserve further investigation and the results of the meta-analysis should be validated in prospective cohorts, these results highlight the potential use of serum KL-6 as a prognostic biomarker for patients with CTD-ILD. This evidence concerns the gene MUC1 and interstitial lung disease.